When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Viloxazine - Wikipedia

   en.wikipedia.org/wiki/Viloxazine

   [6] [1] [5] The immediate-release form has an elimination half-life of 2.5 hours [6] [2] while the half-life of the extended-release form is 7 hours. [1] Viloxazine was first described by 1972 [10] and was marketed as an antidepressant in Europe in 1974. [6] [11] It was not marketed in the United States at this time. [12]

3. Sofosbuvir/velpatasvir - Wikipedia

   en.wikipedia.org/wiki/Sofosbuvir/velpatasvir

   Greater care is required in those who are also infected with hepatitis B. [9] Sofosbuvir works by blocking the NS5B protein and velpatasvir works by blocking the NS5A protein. [9] Sofosbuvir/velpatasvir was approved for medical use in the United States and in Europe in 2016. [9] [6] [7] It is on the World Health Organization's List of Essential ...

4. List of investigational attention deficit hyperactivity ...

   en.wikipedia.org/wiki/List_of_investigational...

   Pirepemat (IRL-752) – "cortical enhancer" / serotonin 5-HT 7 receptor antagonist and α 2C-adrenergic receptor antagonist, other actions [96] [97] Pozanicline (A-87089.0, ABT-089) – α 4 β 2 nicotinic acetylcholine receptor agonist [98] SEP-225432 – serotonin–norepinephrine–dopamine reuptake inhibitor [99]

5. Liquidia's inhaled drug fails to get traditional approval in ...

   www.aol.com/news/us-fda-grants-tentative...

   (Reuters) -The U.S. Food and Drug Administration on Monday delayed traditional approval for Liquidia Corp's inhaled drug for types of lung disorders, and allowed only tentative clearances, sending ...

6. Esaxerenone - Wikipedia

   en.wikipedia.org/wiki/Esaxerenone

   Esaxerenone (INN Tooltip International Nonproprietary Name) (brand name Minnebro; developmental code names CS-3150, XL-550) is a nonsteroidal antimineralocorticoid which was discovered by Exelixis and developed by Daiichi Sankyo Company and is approved in Japan for the treatment of hypertension.

7. US FDA approves Verona Pharma's inhaled COPD therapy - AOL

   www.aol.com/news/us-fda-approves-verona-pharmas...

   (Reuters) -The U.S. Food and Drug Administration has granted approval to a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on ...

8. Velpatasvir - Wikipedia

   en.wikipedia.org/wiki/Velpatasvir

   Plasma protein binding is over 99.5%. It is slowly metabolised by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. It is slowly metabolised by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. While mono hydroxylated and demethylated metabolites have been identified in human blood plasma and faeces, over 98% of the circulating substance is velpatasvir ...

9. FDA approves opioid-free pain medication with 'no sign of ...

   www.aol.com/fda-approves-opioid-free-pain...

   A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...